Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Pasithea Therapeutics (Nasdaq: KTTA) will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference in a virtual session on Thursday, February 26, 2026 at 4:00 PM ET.

Rhea-AI Summary

Pasithea Therapeutics (Nasdaq: KTTA) will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference in a virtual session on Thursday, February 26, 2026 at 4:00 PM ET. CEO Tiago Reis Marques will deliver a 30-minute presentation in Track 2 and management will be available for one-on-one investor meetings.

The presentation will be webcast live and archived for a limited time on the company’s Investors > Events page; a replay will be available after the live event. Registration for the conference is required to join meetings.

Argus Feb 17 session

-2.45% close to close Open Argus

Details

News Market Reaction – KTTA

In the Feb 17 session, KTTA declined 2.45%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights Pasithea’s participation in a major healthcare conference, offering add...

Analysis

This announcement highlights Pasithea’s participation in a major healthcare conference, offering additional visibility for PAS-004, its macrocyclic MEK inhibitor for NF1-PN. Recent history shows meaningful milestones, including positive Phase 1 data and non-dilutive ALS grant funding, alongside substantial equity raises to extend the cash runway through at least the first half of 2028. Investors may watch for updates on clinical timelines, data readouts, and how management communicates development priorities during the presentation.

Key Figures

Conference dates: February 25–26, 2026 Presentation date: February 26, 2026 Presentation time: 4:00–4:30 PM ET +5 more

Conference dates

February 25–26, 2026

Oppenheimer 36th Annual Healthcare Life Sciences Conference

Presentation date

February 26, 2026

Scheduled company presentation date

Presentation time

4:00–4:30 PM ET

Virtual conference Track 2 slot

Share price

$0.7101

Pre-news price context

52-week range

$0.281–$3.79

Pre-news 52-week low and high

Market cap

$16,396,963

Pre-news equity value

Today’s volume

39,633 shares

About 27% of 20-day average volume

Lead program

PAS-004

Next-generation macrocyclic oral MEK inhibitor

Historical Context

5 past events · Latest: Jan 13

5 events

1. Jan 13

   Program outlook update

   24h Move

   -3.3%

   Updated PAS-004 clinical timelines and highlighted funding through at least H1 2028.

2. Dec 02

   Offering closing

   24h Move

   +2.6%

   Closed $60M offering at $0.75 to support R&D and extend cash runway.

3. Nov 28

   Offering pricing

   24h Move

   +38.7%

   Priced $60M equity deal, signaling investor support and improved liquidity.

4. Nov 25

   ALS grant news

   24h Move

   +14.8%

   ALS Association grant of about $1M to fund Phase 1 PAS-004 ALS study.

5. Nov 24

   Phase 1 data update

   24h Move

   +45.3%

   Reported positive safety, PK and PD data from Cohort 7 in PAS-004 cancer trial.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

mek inhibitor, nf1-associated plexiform neurofibromas, nf1-pn

3 terms

mek inhibitor medical

"developing PAS-004, a next-generation macrocyclic oral MEK inhibitor for the treatment"

A MEK inhibitor is a drug that blocks MEK enzymes, which act like a relay in a cell’s growth-signaling pathway; by cutting that relay these drugs can slow or stop uncontrolled cell growth seen in some cancers and other proliferative conditions. Investors care because clinical trial outcomes, safety data, and regulatory approvals determine whether a MEK inhibitor becomes a marketable therapy, directly affecting a developer’s revenue prospects and valuation — like a product passing a crucial safety and sales test.

nf1-associated plexiform neurofibromas medical

"for the treatment of NF1-associated plexiform neurofibromas (NF1-PN), today announced"

Plexiform neurofibromas associated with NF1 are benign but often large and complex nerve‑tumors that arise in people with the inherited condition neurofibromatosis type 1; think of them as tangled bundles of nerve tissue that can grow under the skin or inside the body, causing pain, disfigurement, or functional problems. They matter to investors because they represent a well‑defined patient group with high unmet medical need, regulatory attention, and commercial potential for therapies that can shrink or control these growths, affecting clinical trial value and market opportunity.

nf1-pn medical

"for the treatment of NF1-associated plexiform neurofibromas (NF1-PN), today announced"

A complication of the genetic condition neurofibromatosis type 1 in which benign but often large, irregular tumors called plexiform neurofibromas grow along nerves, sometimes causing pain, disfigurement, or loss of function. For investors this matters because these tumors are hard to treat with surgery or standard therapies, so successful new drugs or devices addressing NF1‑PN can change clinical outcomes, regulatory decisions, and create meaningful market opportunities—think of tangled roots that are difficult to remove without harming the tree.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

– Virtual presentation scheduled for Thursday, February 26, 2026, at 4:00 PM ET –
– Webcast may be accessed here –

MIAMI, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor for the treatment of NF1-associated plexiform neurofibromas (NF1-PN), today announced that Chief Executive Officer Tiago Reis Marques will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, being held in a virtual format February 25–26, 2026.

The Company’s presentation is scheduled for Thursday, Feb 26 at 4:00-4:30 PM ET in Track 2, and the webcast may be viewed here.

In addition to the presentation, management will be available for one-on-one meetings with qualified members of the investor community who are registered to attend the conference.

A live webcast of the presentation will be accessible on the Events page in the Investors section of the Company’s website. A replay will be available following the live event and will be archived for a limited time.

About Pasithea Therapeutics Corp.

Pasithea is a clinical-stage biotechnology company primarily focused on the research and development of its lead drug candidate, PAS-004, a next-generation macrocyclic MEK inhibitor intended for the treatment of RASopathies, MAPK pathway-driven tumors, and other diseases. The Company is currently testing PAS-004 in a Phase 1 clinical trial in advanced cancer patients (NCT06299839), and a Phase 1/1b clinical trial in adult patients with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas (NCT06961565).

Forward Looking Statements

This press release contains statements that constitute “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding the Company’s ongoing Phase 1 clinical trial of PAS-004 in advanced cancer patients, the Company’s Phase 1/1b clinical trial of PAS-004 in adult NF1 patients, and the safety, tolerability, pharmacokinetic (PK), pharmacodynamics (PD) and preliminary efficacy of PAS-004, as well as all other statements, other than statements of historical fact, regarding the Company’s current views and assumptions with respect to future events regarding its business, as well as other statements with respect to the Company’s plans, assumptions, expectations, beliefs and objectives, the success of the Company’s current and future business strategies, product development, pre-clinical studies, clinical studies, clinical and regulatory timelines, market opportunity, competitive position, business strategies, potential growth and financing opportunities and other statements that are predictive in nature. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including risks that future clinical trial results may not match results observed to date, may be negative or ambiguous, or may not reach the level of statistical significance required for regulatory approval, as well as other factors set forth in the Company’s most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q and other filings made with the U.S. Securities and Exchange Commission (SEC). Thus, actual results could be materially different. The Company undertakes no obligation to update these statements whether as a result of new information, future events or otherwise, after the date of this release, except as required by law.

Pasithea Therapeutics Contact

Patrick Gaynes
Investor Relations
pgaynes@pasithea.com 

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Pasithea Therapeutics (KTTA) presenting at the Oppenheimer conference in 2026?

Pasithea is presenting on Thursday, February 26, 2026 at 4:00 PM ET. According to the company, the CEO will speak for a 30-minute slot in Track 2 and management will offer one-on-one meetings for registered attendees.

How can investors watch the Pasithea (KTTA) webcast for the February 26, 2026 presentation?

Investors can watch a live webcast on the company’s Investors > Events page. According to the company, the live webcast will be accessible during the presentation and a replay will be archived for a limited time afterward.

Who from Pasithea (KTTA) will present at the Oppenheimer Healthcare Life Sciences Conference?

Chief Executive Officer Tiago Reis Marques will present for Pasithea. According to the company, he will present in Track 2 and company management will be available for one-on-one investor meetings during the virtual conference.

Will Pasithea (KTTA) offer investor meetings at the Oppenheimer conference on February 25–26, 2026?

Yes, management will be available for one-on-one meetings with qualified, registered investors. According to the company, meetings are open to conference-registered attendees and require qualification and prior scheduling.

How long will Pasithea’s (KTTA) presentation last at the February 26, 2026 event?

The presentation is scheduled for a 30-minute session from 4:00 to 4:30 PM ET. According to the company, the CEO’s slot is in Track 2 and will include the live webcast and subsequent archived replay.

Where will the replay of Pasithea’s (KTTA) Oppenheimer presentation be available and for how long?

A replay will be available on the company’s Investors > Events page and archived for a limited time. According to the company, the replay will be posted after the live event but access will be time-limited.